SIDDALINGAIAH NINGAIAH

Dr. SIDDALINGAIAH NINGAIAH

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2025 in The Lancet Regional Health - Southeast Asia
Verified
Journal Article
Open access
STSubhash Thuluva
Subhash Thuluva
VPVikram Paradkar
Vikram Paradkar
SGSubbaReddy Gunneri
SubbaReddy Gunneri
RMRammohan Reddy Mogulla
Rammohan Reddy Mogulla
VYVijay Yerroju
Vijay Yerroju
ARA. Venkateshwar Rao
A. Venkateshwar Rao
The SARS-CoV-2 virus continues to evolve with recent variants such as the omicron sub-variants potentially exhibiting increased transmissibility. Of note, the XBB.1.5 variant has been associated with vaccine-breakthrough cases. We utilised the same platform previously used to develop CORBEVAX™, an ancestral Wuhan strain COVID-19 RBD subunit vaccine, to now develop an XBB.1.5 RBD subunit vaccine. We evaluated the safety and immunogenicity of the new XBB.1.5 RBD subunit vaccine compared to an ancestral Wuhan strain RBD subunit vaccine. This prospective, single-blind, phase 3 randomised controlled trial was conducted in participants aged 5–80 years. Participants who had not received any other approved COVID-19 vaccine within the last 6 months were enrolled and randomised in a 2:1 ratio to receive two booster doses of either the test vaccine or the control vaccine. The vaccines were administered on Day 0 and Day 28 with immunogenicity assessments on Day 0, Day 28, and Day 42. Safety assessments included the collection of solicited and unsolicited adverse events (AEs) up to Day 56. The primary objective of the study was to demonstrate immunogenic superiority of the test vaccine booster series compared to the control vaccine series. This superiority objective was to be met if the lower limit of the two-sided 95% CI of the anti-XBB.1.5.RBD neutralising antibody (nAb) geometric mean titre (GMT) ratio of test: control was >1.0 on either Day 28 or Day 42. Given the emergence of JN.1 as the prevalent SARS-CoV-2 strain during the conduct of this study, Day 42 anti-JN.1 nAb levels were measured in a post hoc immunogenicity assessment. In addition, anti-XBB.1.5 RBD protein IgG concentrations were also measured by ELISA on Day 0, Day 28, and Day 42. The trial was registered at Clinical Trials Registry–India as CTRI/2024/01/061423. A total of 360 participants (32.8% female) were enrolled and randomised across seven sites in India. The nAb GMT ratio of test: control participants was 2.08 (95% CI 1.64–2.63) on Day 28 and 2.91 (95% CI 2.38–3.56) on Day 42. The geometric mean fold rise (GMFR) of neutralising antibodies (nAb) was 7.637 (95% CI 6.090–9.578) on Day 28 and 17.02 (95% CI 13.79–21.01) on Day 42 in the test booster series arm. The nAb GMFRs in the control booster series arm at the same time points were 3.033 (95% CI 2.340–3.932) and 4.824 (95% CI 3.731–6.236), respectively. Post hoc analyses revealed an nAb GMT ratio of 1.90 (95% CI 1.56–2.31) for test: control against the JN.1 SARS-CoV-2 strain. The safety profile of the new XBB.1.5 RBD subunit vaccine was found to be very similar to that of the ancestral strain vaccine with 59 AEs (about 1 AE for every 8 doses administered) and 27 AEs (a little less than 1 AE for every 8 doses administered) respectively during the study. No serious AEs or AEs of special interest were reported in either the test or control arm of the study. Two cases of pyrexia required medical attention, one in each arm. The new XBB.1.5 RBD subunit vaccine was found to be both safe and robustly immunogenic when administered as a two-dose booster series in individuals aged 5–80 years. In particular, the vaccine induced a significant rise in neutralising antibodies against the XBB.1.5 strain as well as cross-protective neutralising antibodies against the JN.1 SARS-CoV-2 strain. These data are in line with studies of other XBB.1.5 monovalent vaccines and support a positive risk-benefit profile. Real-world studies may provide additional evidence about the effectiveness of this new updated vaccine. Biological E Limited, India.

17 April 2026 in Viruses
Verified
Journal Article
Open access
PDF file
STSubhash Thuluva
Subhash Thuluva
SGSubba Reddy Gunneri
Subba Reddy Gunneri
SNSIDDALINGAIAH NINGAIAH
SIDDALINGAIAH NINGAIAH
VYVijay Yerroju
Vijay Yerroju
RMRammohan Reddy Mogulla
Rammohan Reddy Mogulla
NMNiranjana S. Mahantshetti
Niranjana S. Mahantshetti
Biological E’s BEVAC® is a recombinant DNA hepatitis B vaccine that has been used in India for more than a decade in routine early-life immunization and has recently been prequalified by the World Health Organization (WHO). This multicentre, single-blind, parallel-group, randomized phase IV trial, conducted at seven study sites in India, compared the immunogenicity and safety of BEVAC® with a licensed comparator vaccine (GeneVac-B®, Serum Institute of India Pvt. Ltd, Pune, India.) in healthy term neonates and infants. Participants received three 0.5 mL doses administered intramuscularly at birth (within 24 h), 6 weeks of age, and 14 weeks of age. The primary endpoint was seroprotection (anti-HBs IgG ≥10 mIU/mL) at 28 days after the third dose (Day 126), compared using a non-inferiority margin of −10%. Secondary endpoints included safety and tolerability outcomes through Day 126. A total of 468 neonates were randomized (234 per group), of whom 44% were female. At Day 126, seroprotection rates were 98.2% (95% CI: 95.39, 99.50) with BEVAC® and 99.1% (95% CI: 96.78, 99.89) with the comparator; the between-group difference was −0.9% (95% CI: −3.09, 1.24), meeting the prespecified non-inferiority criterion. Solicited adverse events within 7 days after any dose occurred in 29.1% (95% CI: 23.3, 35.3) of BEVAC® recipients and 35.0% (95% CI: 28.9, 41.5) of comparator recipients, most commonly pyrexia, injection-site pain, and swelling; all were mild-to-moderate. No serious adverse events were reported. BEVAC® demonstrated non-inferior immunogenicity to the licensed comparator and a comparable safety profile.

10 October 2025 in IJID Regions
Verified
Journal Article
Open access
STSubhash Thuluva
Subhash Thuluva
VPVikram Paradkar
Vikram Paradkar
SGSubbaReddy Gunneri
SubbaReddy Gunneri
VYVijay Yerroju
Vijay Yerroju
RMRammohan Reddy Mogulla
Rammohan Reddy Mogulla
CAChitta Sitaram Anjaneylu
Chitta Sitaram Anjaneylu
Vaccines against COVID-19 significantly reduced symptomatic disease and hospitalization. However, waning and diminished protection against emerging variants of concern (VoCs) have warranted booster doses. Clinical studies comparing homologous and heterologous boosters demonstrate enhanced immunogenicity and breakthrough-infection control with heterologous regimens. In this context, we evaluated the safety and immunogenicity of a single heterologous CORBEVAX™ booster in adults in a prospective phase III, randomized, double-blind, placebo-controlled trial. Adults (18-80 years) previously primed ≥6 months earlier with two doses of COVISHIELD™ or COVAXIN™ were randomized 3:1 within each prime group to receive CORBEVAX™ or placebo. Study endpoints included safety, reactogenicity, tolerability, and humoral/cellular immunogenicity. A total of 416 participants (208 per prime group) were enrolled. Post-CORBEVAX™ booster, we observed enhanced humoral responses—significantly increased neutralizing-antibody titers and anti-receptor-binding domain immunoglobulin G—and a T helper 1-skewed cellular response with increased interferon-gamma secretion. A superior post-booster neutralization response against the Omicron VoC was also observed. Adverse events were primarily mild-to-moderate (no adverse events of special interest) with a booster safety profile comparable to placebo. One serious adverse event occurred and was deemed unrelated to the booster. In conclusion, heterologous boosting with CORBEVAX™ substantially enhanced humoral and cellular immunity against SARS-CoV-2 VoCs while being well tolerated.

2 January 2026 in IJID Regions
Verified
Journal Article
Open access
STSubhash Thuluva
Subhash Thuluva
VPVikram Paradkar
Vikram Paradkar
SGSubbaReddy Gunneri
SubbaReddy Gunneri
VYVijay Yerroju
Vijay Yerroju
RMRammohan Reddy Mogulla
Rammohan Reddy Mogulla
CAChitta Sitaram Anjaneylu
Chitta Sitaram Anjaneylu
[This corrects the article DOI: 10.1016/j.ijregi.2025.100786.].

4 October 2025 in The Lancet Regional Health - Southeast Asia
Verified
Journal Article
Open access
STSubhash Thuluva
Subhash Thuluva
VPVikram Paradkar
Vikram Paradkar
SGSubbaReddy Gunneri
SubbaReddy Gunneri
RMRammohan Reddy Mogulla
Rammohan Reddy Mogulla
VYVijay Yerroju
Vijay Yerroju
CDChirag Dhar
Chirag Dhar

28 September 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
STSubhash Thuluva
Subhash Thuluva
SGSubba Reddy Gunneri
Subba Reddy Gunneri
SNSIDDALINGAIAH NINGAIAH
SIDDALINGAIAH NINGAIAH
VYVijay Yerroju
Vijay Yerroju
RMRammohan Reddy Mogulla
Rammohan Reddy Mogulla
JPJog Pramod Prabhakar
Jog Pramod Prabhakar
Background/Objectives: Maternally transferred antibodies protect infants early in life, but high concentrations can reduce immune responses to primary vaccination. CRM197 is a nontoxic mutant of diphtheria toxin that retains antigenic similarity to the native protein. We therefore investigated whether anti-diphtheria antibodies present before vaccination were related to responses against pneumococcal polysaccharides conjugated to CRM197. Methods: This post hoc analysis used data from a multicenter, randomized, single-blind phase III trial in which Indian infants received BE-PCV14/PNEUBEVAX 14® at 6–8, 10–12, and 14–16 weeks of age (commonly referred to as 6–10–14 weeks). Baseline anti-diphtheria toxoid IgG concentrations measured at 6–8 weeks were assessed in relation to serotype-specific pneumococcal IgG responses 28 days after dose 3. We evaluated these associations using categorical and continuous analyses with false-discovery-rate correction for serotype-specific comparisons. Results: Baseline and post-primary results were available for 603 of 650 infants in the co-administration cohort. Post-primary pneumococcal IgG concentrations did not differ significantly across the baseline anti-diphtheria IgG categories. Individual fold rises differed nominally among baseline anti-diphtheria IgG categories for serotype 5, but the difference did not remain significant after multiplicity correction. In the adjusted continuous models, geometric mean ratios (GMRs) associated with each 2-fold increase in baseline anti-diphtheria IgG ranged from 0.978 to 1.011, with no statistically significant associations after false-discovery-rate correction. Analyses stratified by baseline pneumococcal IgG similarly showed no consistent evidence of reduced responses. Conclusions: In this cohort, pre-existing anti-diphtheria toxoid IgG measured before vaccination, which was likely maternally derived, was not associated with a consistent reduction in post-primary serotype-specific pneumococcal IgG responses to CRM197-conjugated BE-PCV14.